Cure Glaucoma Foundation

Pioneering Research. Providing Care.

DALLAS, TX   |  http://cureglaucoma.org

Mission

Cure Glaucoma Foundation is a nonprofit organization dedicated to ending Glaucoma, the leading cause of irreversible blindness worldwide. We fund transformational research, disseminating knowledge, and performing global patient outreach. Through these efforts, and in partnership with others, CGF has positioned itself to be at the forefront in the fight against Glaucoma.

Notes from the nonprofit

Program Service Accomplishments In 2020 the organization operated the following programs. Research - Several unique research initiatives and partnerships are underway or in development: NT-501 Cell Therapy for the Treatment of Glaucoma - the goal of this study is to use a nerve growth factor, called ciliary neurotrophic factor (CNTF), to regenerate nerve tissue damaged from glaucoma. The phase I trial at Stanford University was completed with no serious adverse events and the initial results suggested improvement of visual field, contrast sensitivity and increased nerve thickness. In 2019 and 2020 a grant from Cure Glaucoma Foundation funded Glaucoma Associates of Texas participation in a follow up study that included 10 patients. Our hope is that this study may unlock the key to regenerating nerve tissue in our glaucoma patients, and further our mission to help cure glaucoma. American Glaucoma Society MAPS Grant – 2020 marks the sixth year CGF has funded the AGS MAPS Program. This

Ruling year info

2016

Executive Director

Michael Kettles

President

Steve Love

Main address

10740 North Central Expressway Suite 300

DALLAS, TX 75231 USA

Show more contact info

EIN

81-1231641

NTEE code info

International Relief (Q33)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

CGF is dedicated to preventing vision loss related to glaucoma. Glaucoma causes damage to the eye’s optic nerve and gets worse over time. Often associated with a buildup of pressure inside the eye, glaucoma can cause blindness if left untreated. About half of the estimated three million Americans who have glaucoma are unaware that they have the condition. When glaucoma develops, there are usually no early symptoms. Worldwide, 80 million people have glaucoma. Given the world’s aging population, this number is estimated to increase to 112 million by 2040. In 2020 the WHO estimated 11 million people would be bilaterally blind from glaucoma. The foundation has grown steadily thanks to the volunteer efforts and support of physicians, researchers and donors around the country. In addition, we have developed collaborative relationships with medical institutions around the world and partnerships within the medical industry stateside.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Research

The mission of Cure Glaucoma Foundation (CGF) is to improve glaucoma care by funding transformational research, disseminating knowledge and expanding treatment availability through global outreach efforts.

The founders of CGF believe that by joining together we can pool the collective brainpower of researchers, physicians, patients and volunteers to discover advanced treatments and a cure for this disease.

Thanks to the dedication of pioneering researchers, significant strides in glaucoma care have saved sight in millions of patients worldwide, made possible through research and funding by foundations such as ours.

While research has led to major advances in glaucoma care, adults and children with glaucoma across the globe are still going blind. Glaucoma is the leading cause of irreversible, preventable blindness worldwide. There is more work to be done.

Population(s) Served
Age groups
Health
Social and economic status
Work status and occupations
Ethnic and racial groups

Where we work

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

PROGRAMS
Research - Several unique research initiatives and partnerships are underway or in development (partial list):
-NT-501 Cell Therapy for the Treatment of Glaucoma - the goal of this study is to use a nerve growth factor, called ciliary neurotrophic factor (CNTF), to regenerate nerve tissue damaged from glaucoma.
- American Glaucoma Society MAPS Grant – 2020 marks the sixth year CGF has funded the AGS MAPS Program. This program supports early career glaucoma specialists and scientists by providing tools and resources to further their careers as potential leaders in the science, research and the specialty of glaucoma care.
- Akron Children’s Hospital Clinical Research: Development of an enzyme replacement therapy for primary congenital glaucoma (PCG) – The long-term goal of this project is to develop an Enzyme Replacement Therapy for the treatment of PCG using recombinant CYP1B1. A readily available efficacious and safe alternative method is critically needed to improve patient outcomes and their quality of life.

Global Outreach - CGF sponsors Medical Mission Trips to provide care for patients in underserved countries.
The GDD (Glaucoma Drainage Device) program is designed to teach qualified ophthalmologists in those countries how to implant the drain and, within 18 months, they will in turn train another physician in their resident country how to do the same. By this process CGF, in partnership with New World Medical, will greatly expand access to effective glaucoma therapy for many people.

Access to Care - The purpose of the Access to Care Project (ACP) is to take a proactive approach to reduce the burden of blindness. ACP is designed to address the unmet needs of persons affected by glaucoma with limited financial resources. Patient care provided will include eye exams, surgical, and postoperative clinical care necessary to prevent disease progression and blindness.

CGF has grown steadily thanks to the volunteer efforts and support of physicians, researchers and donors around the country. In addition, we have developed collaborative relationships with medical institutions around the world and partnerships within the medical industry stateside.

Cure Glaucoma Foundation
Pioneering Research & Providing Care

Mission Impact

Since our inception here is a summary of what your support and donations have accomplished:

Including industry backing from pharmaceutical and surgical supply companies (providing in-kind support), and direct financial donations from all of you.

Over the course of 12 mission trips and disaster relief programs there have been:

• 105 glaucoma drainage device implant surgeries performed
• 232 additional surgeries is performed
• 457 physicians and medical staff trained
• 8498 patients have been served
• and a total of $3.5 million in pharmaceutical and surgical supplies, and financial support provided for these trips.
On the research side CGF has funded 10 different initiatives including 8 research studies: 7 of the 8 have yielded favorable results, the total funding has been $307,000.
These programs are possible because of your thoughtful support. Thank you! Sincerely,

Steve Love,
Board President

Mike Kettles,
Executive Director

Financials

Cure Glaucoma Foundation
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

Cure Glaucoma Foundation

Board of directors
as of 01/03/2022
SOURCE: Self-reported by organization
Board chair

Mr. Steve Love

President and CEO of the Dallas-Fort Worth Hospital Council

Dr. Tosin Smith

Glaucoma Associates of Texas

Dr. Ronald Fellman

Glaucoma Associates of Texas

Dr. Joan Taylor

Dr. Michelle Butler

Glaucoma Associates of Texas

Dr. Matthew Emanuel

Glaucoma Associates of Texas

Dr. Davinder Grover

Glaucoma Associates of Texas

Dr. Helen Kornmann

Glaucoma Associates of Texas

Dr. Manjool Shah

University of Michigan, Kellogg Eye Center

Mr. Joe Haggerty

Dr. Brad Jost

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? No
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes

Organizational demographics

SOURCE: Self-reported; last updated 9/14/2021

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Male, Not transgender (cisgender)
Sexual orientation
Heterosexual or Straight
Disability status
Person without a disability

The organization's co-leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Male, Not transgender (cisgender)
Sexual orientation
Heterosexual or Straight
Disability status
Person without a disability

Race & ethnicity

Gender identity

 

Sexual orientation

Disability

We do not display disability information for organizations with fewer than 15 staff.

Equity strategies

Last updated: 09/14/2021

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Policies and processes
  • We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
  • We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.